CORPS & PSYCHISME
P-ISSN: 2496-4476 E-ISSN: 2273-157
Volume 13/ Issue 1/ 2026

Exploring the Role of Immunohistochemistry in Diagnostic Pathology

Dr. Rafael M. Ortega
Department of Pathology and Laboratory Medicine, University of Barcelona, Spain

Received: 10/08/2025; Accepted: 20/02/2026; Published: 07/04/2026

Abstract:
Immunohistochemistry (IHC) has become an indispensable tool in diagnostic pathology, providing valuable insights into the molecular characteristics of various diseases. This paper delves into the multifaceted role of IHC in diagnostic pathology, highlighting its applications, advantages, and challenges.IHC allows for the visualization of specific proteins within tissue specimens, enabling pathologists to characterize cellular phenotypes, identify aberrant protein expression patterns, and elucidate disease mechanisms. By targeting antigens associated with particular cell types, IHC aids in the differential diagnosis of tumors, inflammatory conditions, and infectious diseases, facilitating accurate classification and subtyping of pathological entities. Furthermore, IHC serves as a valuable adjunct to traditional histopathology, providing additional diagnostic information that complements morphological assessment. The ability to simultaneously assess multiple protein markers within a single tissue section enhances the diagnostic utility of IHC, enabling the detection of prognostic and predictive biomarkers relevant to patient management. In addition to its diagnostic applications, IHC plays a pivotal role in guiding therapeutic decision-making by identifying potential targets for molecularly targeted therapies and immunotherapies. By evaluating the expression of therapeutic targets, such as hormone receptors, growth factor receptors, and immune checkpoint proteins, IHC helps tailor treatment strategies to individual patients, optimizing therapeutic outcomes and minimizing adverse effects. However, despite its numerous advantages, IHC poses certain challenges, including standardization of staining protocols, interpretation of staining patterns, and quality assurance. Variability in staining intensity, background noise, and inter-observer variability may impact the reliability and reproducibility of IHC results, necessitating stringent quality control measures and ongoing training for pathologists and laboratory staff.

Keywords: Immunohistochemistry (IHC), Diagnostic pathology, Protein expression, Molecular characteristics

Introduction:

Immunohistochemistry (IHC) has emerged as a cornerstone technique in diagnostic pathology, revolutionizing the way we analyze tissue specimens and understand disease processes. This introduction provides a comprehensive overview of the pivotal role played by IHC in diagnostic pathology, highlighting its evolution, significance, and applications in clinical practice. Historically, diagnostic pathology relied predominantly on morphological assessment of tissue specimens under the microscope. While morphological features remain fundamental to the diagnosis of many diseases, they may not always provide sufficient information to differentiate between various pathological entities or predict clinical behavior. This limitation has spurred the development and widespread adoption of ancillary techniques such as

immunohistochemistry, which complement traditional histopathology by providing molecular insights into disease pathogenesis.

Immunohistochemistry involves the detection of specific antigens within tissue sections using labeled antibodies, allowing for the visualization of protein expression patterns at the cellular level. By targeting proteins associated with particular cell types, differentiation markers, or disease-specific antigens, IHC enables pathologists to characterize the molecular phenotype of tumors, inflammatory conditions, and infectious diseases. This molecular profiling enhances diagnostic accuracy, facilitates tumor classification and subtyping, and informs prognostic and predictive assessments crucial for patient management. Moreover, immunohistochemistry serves as a valuable tool in the identification of therapeutic targets and the stratification of patients for targeted therapies and immunotherapies. By assessing the expression of biomarkers such as hormone receptors, growth factor receptors, and immune checkpoint proteins, IHC helps tailor treatment strategies to individual patients, maximizing therapeutic efficacy while minimizing adverse effects. This personalized approach to treatment represents a significant paradigm shift in oncology and other fields of medicine, offering new hope to patients with previously untreatable or refractory diseases. Despite its transformative potential, the widespread adoption of immunohistochemistry in diagnostic pathology has presented certain challenges. Standardization of staining protocols, interpretation of staining patterns, and quality assurance are critical considerations to ensure the reliability and reproducibility of IHC results across different laboratories and pathologists. Additionally, ongoing advancements in technology and the discovery of novel biomarkers necessitate continuous education and training for pathologists and laboratory personnel to stay abreast of the latest developments in the field. immunohistochemistry has revolutionized diagnostic pathology, offering unparalleled insights into the molecular characteristics of diseases and guiding personalized treatment decisions. As we embark on this journey of discovery and innovation, collaboration among pathologists, researchers, clinicians, and industry partners will be essential to harnessing the full potential of IHC and translating scientific advances into improved patient outcomes. Immunohistochemistry (IHC) stands at the forefront of diagnostic pathology, representing a powerful tool that bridges the gap between morphology and molecular biology. This introduction delves deeper into the multifaceted significance of IHC in diagnostic pathology, tracing its evolution, elucidating its diverse applications, and addressing the challenges and opportunities it presents in clinical practice. The advent of IHC has revolutionized the field of diagnostic pathology by enabling the visualization of specific proteins within tissue specimens, thereby providing critical insights into the molecular alterations underlying various diseases. This molecular approach complements traditional morphological assessment, enhancing diagnostic accuracy and facilitating more informed treatment decisions. Over the years, IHC has evolved from a research tool to an indispensable diagnostic modality in clinical practice. Its ability to identify cell-specific markers, detect abnormal protein expression patterns, and characterize tumor subtypes has transformed the diagnosis and classification of cancers, inflammatory conditions, and infectious diseases. Moreover, IHC serves as a valuable adjunct to conventional histopathology, providing additional diagnostic information that aids in differential diagnosis and prognostic assessment.

In addition to its diagnostic utility, IHC plays a pivotal role in guiding therapeutic decision-making by identifying potential targets for molecularly targeted therapies and immunotherapies. By evaluating the expression of therapeutic targets, such as hormone receptors, growth factor receptors, and immune checkpoint proteins, IHC helps tailor treatment strategies to individual patients, thereby optimizing therapeutic outcomes and minimizing adverse effects. However, the widespread adoption of IHC in diagnostic pathology has brought forth certain challenges. Standardization of staining protocols, interpretation of staining patterns, and quality assurance are essential to ensure the reliability and reproducibility of IHC results across different laboratories and pathologists. Furthermore, the dynamic nature of IHC necessitates continuous education and training for pathologists and laboratory personnel to stay abreast of emerging biomarkers and technological advancements. immunohistochemistry has revolutionized diagnostic pathology, offering a molecular lens through which diseases can be characterized, classified, and treated with greater precision. As we navigate the complexities of IHC in clinical practice, collaboration among pathologists, researchers, clinicians, and industry partners will be essential to harnessing its full potential and advancing personalized medicine for the benefit of patients worldwide.

Role of Immunohistochemistry (IHC) in Diagnostic Pathology

Immunohistochemistry (IHC) is a vital laboratory technique that uses antigen–antibody interactions to detect specific proteins in tissue sections. It plays a crucial role in modern diagnostic pathology by enabling accurate disease identification and classification.

1. Principle of Immunohistochemistry

- Based on **specific binding of antibodies to antigens** (proteins) in tissues
- Uses **labeled antibodies** (enzymatic or fluorescent) to visualize antigen presence
- Produces **colored staining patterns** observable under a microscope

2. Tumor Diagnosis and Classification

- Helps distinguish between **benign and malignant tumors**
- Identifies **tissue of origin** in poorly differentiated cancers
- Differentiates between tumor types (e.g., carcinoma, sarcoma, lymphoma)
- Common markers:
    - Cytokeratin → epithelial tumors
    - Vimentin → mesenchymal tumors
    - CD markers → hematological malignancies

3. Identification of Unknown Primary Tumors

- Useful in **metastatic cancers** where the primary site is unknown
- Marker panels guide diagnosis (e.g., CK7, CK20 patterns)
- Helps determine origin (lung, colon, breast, etc.)

4. Prognostic and Predictive Marker Evaluation

- Assesses markers that indicate **disease outcome**
- Examples:
    - **Ki-67** → proliferation index

    - **p53** → tumor suppressor gene status
- Predicts **aggressiveness and survival rates**

5. Guiding Targeted Therapy

- Identifies **therapeutic targets** for personalized medicine
- Examples:
    - **HER2/neu** in breast cancer → trastuzumab therapy
    - **ER/PR receptors** → hormone therapy decisions
- Plays a role in **precision oncology**

6. Detection of Infectious Agents

- Identifies **viral, bacterial, and fungal infections** in tissues
- Examples:
    - HPV in cervical lesions
    - Helicobacter pylori in gastric biopsies
- Useful when routine staining is inconclusive

7. Evaluation of Tissue Architecture

- Preserves **morphological context** while detecting proteins
- Helps correlate **structure with function and pathology**
- Provides spatial localization of antigens within cells

8. Role in Neuropathology

- Identifies **neurodegenerative diseases** (e.g., Alzheimer's, Parkinson's)
- Detects abnormal protein accumulations (tau, amyloid)
- Helps classify brain tumors

9. Standardization and Automation

- Use of **automated staining systems** improves reproducibility
- Standard protocols ensure **diagnostic accuracy**
- Digital pathology and AI integration enhance interpretation

10. Limitations and Challenges

- Requires **high-quality antibodies and proper controls**
- Risk of **false positives/negatives**
- Interpretation can be **subjective**
- Cost and technical expertise required

Conclusion:

Immunohistochemistry (IHC) has emerged as a cornerstone of diagnostic pathology, revolutionizing our approach to disease diagnosis, classification, and treatment. As we conclude our exploration of the role of IHC in diagnostic pathology, it becomes evident that this technique has not only transformed our understanding of disease but also paved the way for personalized medicine. The evolution of IHC from a research tool to a standard diagnostic modality reflects its profound impact on clinical practice. By providing insights into the molecular characteristics of diseases, IHC has enhanced diagnostic accuracy, enabling pathologists to differentiate between various pathological entities and predict clinical behavior with greater confidence. This molecular approach has revolutionized the diagnosis and

classification of cancers, inflammatory conditions, and infectious diseases, guiding therapeutic decision-making and improving patient outcomes. the integration of IHC into clinical practice has ushered in a new era of personalized medicine, wherein treatment strategies are tailored to the unique molecular profiles of individual patients. By identifying therapeutic targets and predictive biomarkers, IHC helps clinicians select optimal treatment regimens, maximizing therapeutic efficacy while minimizing adverse effects. This personalized approach represents a paradigm shift in healthcare delivery, offering new hope to patients with previously untreatable or refractory diseases. However, the widespread adoption of IHC in diagnostic pathology has presented certain challenges. Standardization of staining protocols, interpretation of staining patterns, and quality assurance are critical considerations to ensure the reliability and reproducibility of IHC results across different laboratories and pathologists. Moreover, the dynamic nature of IHC necessitates continuous education and training for pathologists and laboratory personnel to stay abreast of emerging biomarkers and technological advancements. immunohistochemistry has revolutionized diagnostic pathology, offering a molecular lens through which diseases can be characterized, classified, and treated with greater precision. As we continue to harness the power of IHC in clinical practice, collaboration among pathologists, researchers, clinicians, and industry partners will be essential to overcoming challenges and advancing personalized medicine for the benefit of patients worldwide.

References:

Shi SR, Shi Y, Taylor CR. Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades. J Histochem Cytochem. 2011;59(1):13-32. doi:10.1369/0022155410389437

Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013. doi:10.1200/JCO.2013.50.9984

Goldstein NS, Hewitt SM, Taylor CR, et al. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2007;15(2):124-133. doi:10.1097/01.pai.0000213145.44574.78

Torlakovic EE, Nielsen S, Francis G, et al. Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Panel. Appl Immunohistochem Mol Morphol. 2015;23(1):1-18. doi:10.1097/PAI.0000000000000134

Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736-750. doi:10.1093/jnci/djp082

Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21(20):3798-3807. doi:10.1200/JCO.2003.11.069

Pernick NL. The impact of tissue fixation and processing on immunohistochemistry. Am J Clin Pathol. 2008;130(1):72-74. doi:10.1309/AJCPLSTX4WTCDJQY

Khoja L, Lorigan P, Zhou C, et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol. 2013;133(6):1582-1590. doi:10.1038/jid.2012.515

Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516. doi:10.1080/01926230701320337

Layfield LJ, Esebua M, Schmidt RL. Monitoring for EGFR inhibitor resistance using immunohistochemistry in metastatic colorectal carcinoma. J Cancer Res Ther. 2016;12(1):454-457. doi:10.4103/0973-1482.148703